Advertisement
Strategies & Technologies Driving Drug Discovery to Market
Subscribe to Drug Discovery & Development All
View Sample

FREE Email Newsletter

DDD Update

Daily news and top headlines for drug research professionals

NIH Awards Aim to Improve Understanding of Cell Pathways

September 15, 2014 10:33 am | News | Comments

Building on a successful three-year pilot project, the National Institutes of Health has awarded more than $64 million to six research institutions to create a database of human cellular responses. Discovering such cell responses will improve scientists’ understanding of cell pathways and aid in the development of new therapies. Read more...

TOPICS:

Gilead to License Generic Version of Sovaldi

September 15, 2014 8:41 am | by The Associated Press | News | Comments

Gilead Sciences has reached a deal with several generic drugmakers to produce cheaper versions of its popular, expensive hepatitis C drug Sovaldi for use in developing countries. Read more...                 

TOPICS:

Researchers Find Defense Mechanism Against Viruses

September 12, 2014 2:00 pm | News | Comments

Researchers have discovered that a known quality control mechanism in human, animal and plant cells is active against viruses. They think it might represent one of the oldest defense mechanisms against viruses in evolutionary history.

TOPICS:
Advertisement

BioTime, Charity Partner for Trial of Vaccine for Lung Cancer

September 12, 2014 2:00 pm | News | Comments

BioTime, Inc. announced that its subsidiary Asterias Biotherapeutics, Inc. has reached an agreement with Cancer Research UK and Cancer Research Technology— the charity’s development and commercialization arm— to conduct a clinical trial of Asterias’ novel immunotherapy treatment AST-VAC2 in subjects with non-small cell lung cancer.

TOPICS:

Novartis, Penn Team for Cellular Therapeutics Center

September 12, 2014 2:00 pm | News | Comments

The Univ. of Pennsylvania has reached an important milestone in its alliance with Novartis as it unveiled plans for the construction of a first-of-its-kind Center for Advanced Cellular Therapeutics on the Penn Medicine campus in Philadelphia.

TOPICS:

FDA Backs Injection for Obesity

September 12, 2014 2:00 pm | News | Comments

Federal health experts say Novo Nordisk's diabetes drug Victoza should be approved for a new use in treating obesity. The panel of Food and Drug Administration advisers voted 14-1 that the injectable drug's benefits outweigh its risks for patients who are obese or dangerously overweight.

TOPICS:

Scientists Can Reset Human Stem Cells

September 12, 2014 2:00 pm | News | Comments

Scientists have successfully reset human pluripotent stem cells to the earliest developmental state– equivalent to cells found in an embryo before it implants in the womb (seven to nine days old). These pristine stem cells may mark the true starting point for human development, but have until now been impossible to replicate in the lab.

TOPICS:

Phase 2a Begins for Genocea's Pneumococcus Vaccine

September 12, 2014 7:00 am | News | Comments

Genocea Biosciences, Inc. announced the initiation of a Phase 2a trial for GEN-004, the company’s universal vaccine candidate against pneumococcus. The trial is designed to evaluate the effect of dosing with GEN-004 on the frequency, magnitude and duration of colonization by pneumococcus in the nasopharynx of healthy adults.

TOPICS:
Advertisement

Biogen Shows Positive Effects in Year Two of RMS Drug Trial

September 12, 2014 7:00 am | News | Comments

Biogen Idec announced new data from the second year of its Phase 3 ADVANCE clinical trial that show the positive treatment effects of PLEGRIDY (peginterferon beta-1a) were maintained in people with relapsing forms of multiple sclerosis (RMS) beyond the first year of the study. 

TOPICS:

Data Validate 3x/Week MS Injections

September 12, 2014 7:00 am | News | Comments

Teva Pharmaceutical Industries Ltd. announced new data from the open-label Phase IIIb GLatiramer Acetate low frequenCy safety and patIent ExpeRience (GLACIER) study, comparing the safety and tolerability of three-times-a-week COPAXONE (glatiramer acetate injection) 40 mg to daily COPAXONE 20 mg in patients with relapsing-remitting multiple sclerosis (RRMS). 

TOPICS:

Using Antibiotics to Negate Heart Side Effects

September 12, 2014 7:00 am | News | Comments

A research team from the University of Bristol is looking at whether an antibiotic has the potential to prevent or treat irregular heartbeats brought on by other medicines. A research team will study whether low levels of the antibiotic erythromycin can block negative side effects, and will further investigate the mechanisms involved.

TOPICS:

University Working Toward Long-Acting HIV Drugs

September 12, 2014 7:00 am | News | Comments

HIV drugs that only need to be taken once a month are to be developed at the University of Liverpool in a bid to overcome the problem of "pill fatigue." To help address the problem, scientists are developing injections that provide therapeutic exposure to the drugs for at least a month and may replace daily tablets in some patients.

TOPICS:

SEM for 3-D Volume Imaging of Cells and Tissues

September 11, 2014 3:53 pm | Product Releases | Comments

The Teneo VS scanning electron microscope (SEM) from FEI offers a VolumeScope capability for life science applications. 

Our Microbes Are a Rich Source of Drugs

September 11, 2014 3:08 pm | News | Comments

Bacteria that normally live in and upon us have genetic blueprints that enable them to make thousands of molecules that act like drugs, and some of these molecules might serve as the basis for new human therapeutics, according to a new study. Read more...

TOPICS:

Compound Protects Brain Cells After TBI

September 11, 2014 3:03 pm | News | Comments

A new class of compounds has now been shown to protect brain cells from the type of damage caused by blast-mediated traumatic brain injury (TBI). Read more...                           

TOPICS:

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading